Planning The Breast Boost: Dosimetric Comparison Of Cyberknife, Photon Mini Tangents, Imrt, And Electron Techniques

J. Fan,S. Hayes,G. Freedman,P. Anderson,J. Li,L. Wang,L. Jin,R. Price,C. Ma
DOI: https://doi.org/10.1016/j.ijrobp.2010.07.1826
2010-01-01
Abstract:Conventional breast conservation treatment consists of breast-conserving surgery and whole breast radiotherapy followed by a boost to the tumor bed. The purpose of this study is to compare CyberKnife to conventional photon mini tangents, intensity modulated radiation therapy (IMRT) and electrons in terms of conformity and dose to normal tissues. Treatment plans were generated and compared using all four techniques for each of 15 patients with early stage breast cancer after breast-conserving surgery (6 right, 9 left). Surgical clips were used to define the clinical target volumes (CTV) of the excision cavities. Treatment plans were normalized to make the 95% isodose line covers 100% of the CTV. The prescription dose was 10 Gy in 2 fractions for CyberKnife and 10 Gy in 5 fractions for the other techniques. This dose/fractionation scheme was chosen to simplify the comparison. The Monte Carlo dose calculation algorithm was used to ensure accuracy of dose calculation to the lung. The CTV conformity index (CI) and the dose volume histograms for the normal tissues for each technique were compared. The mean CI with CyberKnife was 1.22, compared to 4.8, 2.1 and 2.4 for mini tangents, IMRT and electron techniques, respectively. The mean maximum lung dose was 6.0 Gy with CyberKnife, compared to 8.4 Gy with mini tangents, 7.9Gy with IMRT and 8.2 Gy with electrons. The V20 and V40 for the ipsilateral lung was 12.4% and 1.2% with CyberKnife, compared to 15.1% and 12.2% with mini tangents, 7.2% and 4.3% with IMRT and 9.6% and 5.2% with electrons. The skin and heart doses were also significantly decreased for deep tumor beds with CyberKnife. The CyberKnife delivers a significantly more conformal dose to the lumpectomy cavity compared with other traditional boost techniques, and also allows for real time tracking using the surgical clips as fiducial markers. These advantages could result in reduced toxicity by reducing the dose to the surrounding breast tissue outside of the boost, skin, chest wall, lung or heart. Future research in needed to determine if CyberKnife radiosurgery boost using advanced target tracking techniques could improve local control by allowing radiation dose escalation in early stage breast cancer.
What problem does this paper attempt to address?